This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=110 http://www.lsis.com/goto/r110/rss 2012-02-05T11:11:10+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=110 Abstract The effectiveness of phosphate binders can be assessed by evaluating urinary phosphorus excretion in healthy volunteers, which indicates the ability of the phosphate binder to reduce gastrointestinal phosphate absorption. Healthy volunteers were enrolled into one of five separate randomized trials; four were open label and one double blind. Following a screening period of ?28 days, participants received differing tablets containing lanthanum carbonate [LC, 3000 mg/day of elemental (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=110 Canaan Partners, a global venture fund with $3.5 billion under management, has raised $600 million to invest in technology and health-care companies. Canaan, based in Menlo Park, California, will spend two- thirds of the fund on digital media, Internet, mobile and other technology companies, and a third is designated for pharmaceutical, medical device and health-care investments, the company said today in a statement. This is Canaan s ninth fund. Previous investments included Advanced (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=110 ROCKVILLE, Md.-(BUSINESS WIRE)- Supernus Pharmaceuticals, Inc. today announced that in December 2011 it closed two transactions through which it raised $42 million. The sale of its TCD Royalty Subsidiary, which was established in April 2008 to securitize royalties that were generated by Sanctura XR and Oracea, generated $27 million, while the second transaction, the issuance of venture debt, generated $15 million. Proceeds from the transactions will be used to prepare for the commercial (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=110 PHILADELPHIA, Dec. 2, 2011 /PRNewswire/ - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has reached an agreement with the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) to conduct additional clinical trials to confirm the clinical benefit of ProAmatine (midodrine HCl), a medicine approved in 1996 under Subpart H (an accelerated approval process) for the treatment of symptomatic orthostatic (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=110 OBJECTIVE: This study examined the effect of armodafinil on late-in-shift clinical condition, wakefulness, and overall functioning of patients with shift work disorder. METHODS: Patients with clinically diagnosed shift work disorder received armodafinil or placebo on nights worked for 6 weeks. Patients included in the study experienced late-in-shift sleepiness between 4 AM and 8 AM (Karolinska Sleepiness Scale ?6) and were functionally impaired (Global Assessment of Functioning text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=110 Background: Patients with ulcerative colitis (UC) frequently require long-term therapy to prevent relapse. Treatments such as 5-aminosalicylic acid (5-ASA [mesalazine]) are efficacious and well tolerated, but adherence to treatment is often poor. Objective: This discrete-choice experiment (DCE) was conducted to estimate differences in patient preferences for 5-ASA treatment in mild-to-moderate UC based on levels of self-reported adherence. Inclusion of patients residing in the US, UK, Germany, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 EDISON, N.J.-(BUSINESS WIRE)-Oceana Therapeutics LLC, a privately owned global company focused on commercializing best-in-class specialty therapeutics, today announced it has entered into a definitive agreement for the sale of its operating subsidiary, Oceana Therapeutics, Inc. to Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) of Raleigh, NC. The all cash transaction valued at $300 million has been approved by the Board of Directors of each company and is subject to routine closing conditions, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=110 EDISON, N.J.-(BUSINESS WIRE)-Oceana Therapeutics LLC, a privately owned global company focused on commercializing best-in-class specialty therapeutics, today announced it has entered into a definitive agreement for the sale of its operating subsidiary, Oceana Therapeutics, Inc. to Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) of Raleigh, NC. The all cash transaction valued at $300 million has been approved by the Board of Directors of each company and is subject to routine closing conditions, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 PHILADELPHIA-(BUSINESS WIRE)-High schools throughout Southeastern Pennsylvania are invited to participate in Shire s Great Food Fight! Benefitting Philabundance to help raise food in support of families in need across the Greater Philadelphia region. All participating schools will have the opportunity to compete for a prize of $10,000, $5,000 or $1,000 while joining forces to achieve an ambitious goal: collect 100 tons of food which is equivalent to 200,000 meals for Philabundance over a two (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=110 BACKGROUND: Adhesive small bowel obstruction (ASBO) is an important cause of hospital admission, is associated with significant morbidity and mortality, and therefore is a substantial burden for healthcare systems worldwide. Icodextrin 4% solution (Adept, Shire Pharmaceuticals, UK) is a high-molecular-weight a-1,4 glucose polymer approved in Europe for use as intraoperative lavage and postoperative instillation to reduce the occurrence of post-surgery intra-abdominal (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 BEDMINSTER, N.J.-(BUSINESS WIRE)-NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today reported its third quarter 2011 financial results. We are also pleased that we added two early clinical-stage calcilytic compounds to our pipeline - NPSP790 and NPSP795 - and we are eager to assess their potential in rare endocrine disorders like ADHH. NPS reported a net loss of $12.3 million or (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=110 Shire plc presented positive top-level results of their first European phase III study of lisdexamfetamine dimesylate (LDX), designed for children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder (ADHD). LDX is administered once daily and is the first chemically formulated long-acting, prodrug of dexamfetamine for treating ADHD. It is currently only licensed in the US, Brazil and Canada. Results of the phase III study demonstrated LDXs efficacy on the primary (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 PHILADELPHIA-(BUSINESS WIRE)-Shire, a global specialty biopharmaceutical company, has expanded its ADHD Scholarship Program. The program is for individuals in the United States diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) who are pursuing higher education at a college, vocational school or technical school. Fifty winners will be selected in 2012, twice as many as in the first year. There are thousands of high school seniors, college students, and adults going on to higher (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 BEDMINSTER, N.J.-(BUSINESS WIRE)-NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the appointment of Eric Pauwels as senior vice president and chief commercial officer. Pauwels brings more than 25 years of global commercial experience to NPS Pharmaceuticals, having held management positions in top-tier U.S. and European biopharmaceutical companies. At Shire HGT, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 PHILADELPHIA-(BUSINESS WIRE)-In Pennsylvania, one in 10 kids is affected by poverty; in Philadelphia, the number is one in three. They re children from low-income homes or who are homeless and living in shelters. Often, they re the children who live next door and whose parents have lost their jobs. That s why Shire is calling on local elementary and middle schools, families with children and youth and community organizations to participate in Shire s Big Give. The goal: to deliver clothing, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 ALPHARETTA, Ga.-(BUSINESS WIRE)-SANUWAVE Health, Inc. (OTCBB: SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today announced that Ron Sparks, age 56, a 34-year veteran of the medical device industry, has joined the Company s Board of Directors. Mr. Sparks is the Chief Executive Officer and Chairman at Navilyst Medical, Inc., a best-in-class image-guided medical (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e733fd/gastrointestinal_d) has announced the addition of the "Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth" report to their offering. Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth Gastrointestinal Disorder Therapeutics Market to 2017 - (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 LONDON-(BUSINESS WIRE)-By 2017 the gastrointestinal disorder therapeutics market is expected to be worth $18.3 billion by 2017, according to a new report available on companiesandmarkets.com. Gastrointestinal conditions tend to be most common in the elderly, and while the ageing demographic has contributed to sector growth, the market forecast figure still represents a decline of 4.8% over the 2010-2017 reporting period; attributed to the maturing global market. Gastrointestinal Disorder (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=110 September 08, 2011 - Athersys Inc. (NASDAQ: ATHX) is a company focused on regenerative medicine, similar to companies like Osiris Therapeutics Inc. (NASDAQ: OSIR), Mesoblast (ASX:MSB), and Cytori (NASDQ: CYTX) and others that are developing a stem cell platform to target a range of disease indications. From heart disease to ischemic stroke, the company s MultiStem platform offers multiple advantages over traditional approaches to treatment, as well as other approaches to regenerative medicine (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/717229/the_worlds_top_10) has announced the addition of the "The World's Top 100 Pharmaceutical Companies" report to their offering. Did you know? Dr. Jeremy Levin is Senior Vice President, Strategy, Alliances and Transactions at Bristol-Myers Squibb. The Email Address Format at Orion Corporation is Firstname.Lastname@Orion.Fi On July 21, 2011, Kissei Pharmaceutical Co., Ltd. announced the launch of (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/channels/?query=110 Shire plc announced positive data from several studies designed to evaluate the safety of switching to REPLAGAL (agalsidase alfa) from Fabrazyme (agalsidase beta) and the long-term safety and benefits of switching to VPRIV (velaglucerase alfa) from Cerezyme (imiglucerase). Study results are being presented at the 2011 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM)."The volume of data presented to the medical community at SSIEM provides compelling evidence (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=110 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for FIRAZYR (icatibant injection) for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. "Until now, HAE patients faced challenges gaining rapid access to acute treatment such as the need to travel to the physician's office or hospital," said Timothy Craig, Professor of (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=110 Westport, Conn. August 24, 2011 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that Advanced BioHealing (ABH), its regenerative medicine business, has concluded its phase three pivotal trial of Dermagraft in subjects with venous leg ulcers. Following preliminary analysis of the top-line results, the decision has been made not to pursue the venous leg ulcer indication. The international pivotal trial, which enrolled more than 500 patients in (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 PHILADELPHIA-(BUSINESS WIRE)-Shire has named the first recipients of its new ADHD Scholarship program. Twenty-five individuals diagnosed with Attention-Deficit / Hyperactivity Disorder (ADHD) who are going on to higher education were selected from 269 applications across the United States. They were recognized for their involvement in school and community activities, work experience, honors and awards, and their personal essays. At Shire, we recognize that the transition to higher education (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 EDISON, N.J.-(BUSINESS WIRE)-Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, today announced that the Company s President & COO, David S. Tierney, MD, has been featured in PharmaVOICE s 2011 listing of the 100 Most Inspiring People in the Life Sciences Industry. David s abilities as a life-science professional are exceptional and have significantly influenced the dramatic growth of Oceana from a start-up in mid (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=110 ?Prucalopride (Resolor - Shire Pharmaceuticals Ltd) is licensed, only in women, for symptomatic treatment of chronic constipation when laxatives fail to provide adequate relief.1 It is promoted as being "effective in helping to restore normal bowel movements and alleviating a broad range of constipation symptoms in women." Here we review the evidence for prucalopride and consider the drug's place as a treatment for chronic constipation. |-| Drug Ther Bull. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=110 Having posted a strong set of second-quarter results earlier this month, Shire Pharmaceuticals continues to develop a balance sheet that would impress any potential acquirer, according to analysts at Matrix Group. In a research note, the analysts say the firm "remains a highly attractive M&A target", as Shire "is now a diversified specialty pharmaceutical company with three strong growth engines". These are its attention-deficit hyperactivity disorder franchise, Shire HGT (the business unit (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=110 Dublin, Ireland July 27, 2011 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that Susan Kilsby will join the Board of Directors on September 1st, 2011. On joining the Board, Ms Kilsby will become a member of the Company s Audit, Compliance & Risk Committee. In addition, current Board Directors Bill Burns and David Stout will join the Nomination Committee and Remuneration Committee respectively with immediate effect. Susan Kilsby has a (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=110 To review the literature describing impairments in educational, occupational, and social functioning in adults with attentiondeficit/hyperactivity disorder (ADHD), current treatment trends, and factors that may influence the abuse potential of long-acting medications used to treat ADHD in adults. |-| J Psychiatr Pract. |-| Mao AR, Babcock T, Brams M. |-| *Baylor College of Medicine, Houston, TX ?Shire Pharmaceuticals, Wayne, PA. text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=110 Shire plc (LSE: SHP; NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved Lialda (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis. This approval is based on results from a six-month study demonstrating the safety and effectiveness of Lialda in maintaining endoscopic remission in adult patients. This approval follows the previous indication of Lialda approved (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=110 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Lialda (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis. This approval is based on results from a six-month study demonstrating the safety and effectiveness of Lialda in maintaining endoscopic remission in adult patients. This approval follows the previous indication of Lialda (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=110 Shire Plc (SHP), Ireland s biggest drugmaker, is aiming to introduce a medicine that quells the urge to overeat. Just don t call it a diet drug. After Alkermes Inc. (ALKS) last week stopped developing a similar medicine, Shire became the top candidate to develop the first approved drug to combat binge-eating disorder. The Dublin-based company says its treatment, Vyvanse, now marketed for hyperactivity, may limit binging by interacting with brain chemicals that affect mood, motivation and (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=110 July 8, 2011 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has been named œBusiness of the Year  at the 2011 First Women Awards for being the only FTSE 100 business where women make up at least 50 per cent of the executive leadership team. The First Women awards, now in their seventh year, aims to œunearth women whose achievement and individual actions have helped and are helping to remove barriers and open up opportunities for others to follow. It (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 NEEDHAM, Mass.-(BUSINESS WIRE)-Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced the appointment of Ronald A. Pepin, Ph.D. to Senior Vice President and Chief Business Officer, effective immediately. Dr. Pepin brings to Celldex more than 20 years of business development and senior leadership experience in the biotechnology and pharmaceutical industries. The Company s antibody-based cancer immunotherapy pipeline is among the most promising in the industry today. I look forward to (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 EDISON, N.J.-(BUSINESS WIRE)-Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, today announced that John T. Spitznagel, Chairman & CEO, and David S. Tierney, MD, President & COO, have been named Ernst & Young Entrepreneur Of The Year 2011 New Jersey region award winners. Winning in the Emerging category is particularly rewarding, because it reflects the rapid growth of Oceana in a relatively short time. Thus, the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 WOBURN, Mass.-(BUSINESS WIRE)-Aeris Therapeutics, LLC today announced the appointments of Dennis D Oria as its new Vice President of International Sales and Marketing and Mr. Charles R. Carter as Chief Financial Officer. œAeris has made great strides in the development phase of the AeriSeal System,  said David Dove, M.D., President and CEO. œDennis and Charley bring a great deal of combined experience that will enable us to drive our commercialization efforts. We are eager to make the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 WAYNE, Pa.-(BUSINESS WIRE)-Safeguard Scientifics, Inc. (NYSE: SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that its aggregate cash proceeds from the completed sale of life sciences partner company Advanced BioHealing, Inc. (ABH) to Shire plc (LSE: SHP, NASDAQ: SHPGY) are $145.4 million. In addition, $7.3 million will be held in escrow pending the expiration of an escrow period expiring March 31, 2012. Safeguard s total (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f12cf3/pediatric_drugs_an) has announced the addition of the "Pediatric Drugs and Vaccines - Global Strategic Business Report" report to their offering. Pediatric Drugs and Vaccines - Global Strategic Business Report This report analyzes the worldwide markets for Pediatric Drugs and Vaccines in US$ Million by the following Product Segments: Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=110 WAYNE, Pa.-(BUSINESS WIRE)-Safeguard Scientifics, Inc. (NYSE: SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that its aggregate cash proceeds from the completed sale of life sciences partner company Advanced BioHealing, Inc. (ABH) to Shire plc (LSE: SHP, NASDAQ: SHPGY) are $145.4 million. In addition, $7.3 million will be held in escrow pending the expiration of an escrow period expiring March 31, 2012. Safeguard s total (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=110 June 27, 2011 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has been named œCompany of the Year  at the European Mediscience Awards 2011. Shire is the only company to have ever won the award twice, having won it also in June 2010. Over 300 quoted European mediscience companies are eligible for the European Mediscience Awards, provided that the majority of the business of the company, and its subsidiaries are in the healthcare, medical, pharmaceutical, (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=110 An FDA Pulmonary-Allergy Drugs Advisory Committee voted in favor 11 to 1 (one abstention) of approving Firazyr (22150, icatibant solution), a medication for the treatment of hereditary angioedema in patients aged 18+ years. Although the Committee's recommendations are not binding, the FDA nearly always goes along with what the Panel (Committee) advice. The FDA is expected to make its final decision on 25th August, 2011. According to the makers of Firazyr, Shire PLC, a UK pharmaceutical (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=110 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced that the Pulmonary-Allergy Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) recommended, by a vote of twelve to one, that the efficacy and safety data provides substantial evidence to support approval of FIRAZYR (icatibant) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 18 years and older. In addition, by a vote of eleven to one, with one (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=110 DUBLIN, Ireland and LEXINGTON, Massachusetts, June 23, 2011 /PRNewswire via COMTEX/ - Shire plc /quotes/zigman/508678 UK:SHP +0.97% /quotes/zigman/66975/quotes/nls/shpgy SHPGY -0.53% , the global specialty biopharmaceutical company, today announced that the Pulmonary-Allergy Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) recommended, by a vote of twelve to one, that the efficacy and safety data provides substantial evidence to support approval of FIRAZYR (icatibant) (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=110 Dublin, Ireland and Lexington, MA, US June 24, 2011 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the European Medicines Agency has approved the purification of REPLAGAL (agalsidase alfa) drug substance at its new manufacturing facility in Lexington, MA, US. REPLAGAL, Shire s enzyme replacement therapy for the treatment of Fabry disease is the first product that will be made available to patients from the new facility. With this (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=110 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced key interim data from the ongoing Firazyr (icatibant) self-administration study of icatibant. The data were presented in oral and poster presentations at the European Academy of Allergy and Clinical Immunology (EAACI) congress. Interim data from 56 patients enrolled in the Phase IIIb Evaluation of the Safety of Self-Administration With Icatibant (EASSI), showed that self-administration of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 WAYNE, Pa.-(BUSINESS WIRE)-Safeguard Scientifics, Inc. (NYSE: SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that technology partner company Portico Systems, Inc. has signed a definitive agreement to be acquired by McKesson. Five years ago, when Safeguard first provided us with growth equity capital as part of our Series A financing, we were a fledgling company with a big dream McKesson has agreed to pay $90 million, in cash, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=110 Shire Plc's drug to treat severe swelling caused by a rare genetic disorder showed effectiveness in a key clinical trial, U.S. Food and Drug Administration staff said on Tuesday. The injected drug, Firazyr, is under U.S. review for treating attacks suffered by patients with hereditary angioedema. FDA staff issued a report on the drug, which is approved in other countries, ahead of a federal advisory committee meeting to review the medicine on Thursday. The clinical trial, known as FAST-3, was (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/b3bc62/schizophrenia_ther) has announced the addition of the "Schizophrenia Therapeutics Market in the US: Market Forecast, Patient Flow, and Competitive Landscape" report to their offering. Schizophrenia Therapeutics Market in the US: Market Forecast, Patient Flow, and Competitive Landscape The Global Schizophrenia therapeutics market was valued at $6.7 billion in 2010, and is expected to reach $7.3 (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=110 PHILADELPHIA-(BUSINESS WIRE)-Shire announces a distinguished panel of judges for their new scholarship program being offered to students in the United States diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). The president of the Attention Deficit Disorder Association (ADDA), the CEO of Children and Adults with Attention Deficit/Hyperactivity Disorder (CHADD), and the president of the American Professional Society of ADHD and Related Disorders (APSARD) are among those who will (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=110 Throughout the Pharmaceutical and Biotechnology industries, licensing partnerships are becoming the go-to method for developing and commercializing new therapies. This strategy of bringing together companies of varied size and stage of development with vastly different sets of resources can pose challenges throughout the process. This upcoming program will bring together executives from a variety of organizations in order to provide attendees with the opportunity to hear from the brightest (…)